https://pharmaphorum.com/ en Fri, 26 Jul 2024 19:04:59 +0000 Fri, 26 Jul 2024 13:25:01 +0000 https://pharmaphorum.com/news/shock-move-eu-panel-rejects-alzheimers-drug-leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green light to the drug.In the surprise development, the CHMP said that the benefits of the anti-amyloid antibody – which was aiming to become the first disease-modifying drug for Alzheimer's in the EU – are outweighed by the risk of serious adverse events. Phil.Taylor https://pharmaphorum.com/news/shock-move-eu-panel-rejects-alzheimers-drug-leqembi 2024-07-26T13:25:01+0000 Feed - News and features https://pharmaphorum.com/news/third-arcs-165m-t-cell-engagers-plus-other-bio-rounds This week's round-up of new financings in the biotech world is headed by a big round for Third Arc, a specialist in T-cell engager antibodies, with Autobahn, Brenig, Confo, and GRO Bio also in on the action.First up, Third Arc Bio, seeded at Omega Funds and led by former Johnson & Johnson executives, which pocketed an impressive $165 million in a first round led by Vida Ventures and co-led by Cormorant Asset Management and Hillhouse Investment. Omega supported the round alongside other backers. Phil.Taylor https://pharmaphorum.com/news/third-arcs-165m-t-cell-engagers-plus-other-bio-rounds 2024-07-26T11:12:05+0000 Feed - News and features https://pharmaphorum.com/news/az-joins-call-new-uk-pm-back-oxford-cambridge-hub In a letter to the new UK Prime Minister Keir Starmer, leading figures in industry and academia have called for a plan to turn the Oxford-Cambridge region into the 'crown jewel' of the nation's economy.The signatories, who include AstraZeneca's head of discovery sciences Steve Rees and the vice-chancellors of the universities of Oxford and Cambridge, claim that investment in the area could add £50 billion to the UK economy by the end of the decade. Phil.Taylor https://pharmaphorum.com/news/az-joins-call-new-uk-pm-back-oxford-cambridge-hub 2024-07-26T09:49:25+0000 Feed - News and features https://pharmaphorum.com/news/pfizers-haemophilia-b-gene-therapy-gets-eu-green-light There will soon be two gene therapies available for patients with haemophilia B in the EU after the European Commission approved Pfizer's fidanacogene elaparvovec under the Durveqtix brand name. Phil.Taylor https://pharmaphorum.com/news/pfizers-haemophilia-b-gene-therapy-gets-eu-green-light 2024-07-26T08:50:58+0000 Feed - News and features https://pharmaphorum.com/news/shingles-shot-could-be-simple-way-delay-dementia Vaccination with GSK's recombinant shingles vaccine, Shingrix, could delay the onset of dementia, according to researchers in the UK.A study published in Nature Medicine suggests that people administered Shingrix have a lower risk of dementia compared to those given Zostavax - an older shingles shot based on a different technology – and builds on earlier research suggesting a benefit from this type of vaccination. Phil.Taylor https://pharmaphorum.com/news/shingles-shot-could-be-simple-way-delay-dementia 2024-07-26T07:55:53+0000 Feed - News and features